China is a major player in the pharmaceutical industry, but it has not yet become a true global powerhouse. With the rising barriers to new drug development and increasingly robust patent protection systems, Chinese pharmaceutical companies must confront an unavoidable reality: to align with international standards and strive to develop new drugs with independent intellectual property, or risk being left behind.
From a production standpoint, China possesses strong manufacturing capabilities. Its formulation processing capacity ranks first globally, while its bulk drug production is second only to India, accounting for 25% of the global API market. The output of certain chemical drugs—especially antibiotics and vitamin C—remains the highest in the world. However, when it comes to R&D, China still lags significantly. Among the top-selling drugs in the global Western medicine market, few are patented products from China. The lack of independent intellectual property and the widespread issue of product homogenization are serious problems. Many generic drugs are produced by dozens of companies simultaneously, leading to market chaos, insufficient investment, and a vicious cycle of low innovation rates.
According to Wang Xiaoliang, director of the Institute of Materia Medica at the Chinese Academy of Medical Sciences, Chinese new drugs often lack "substance," meaning they lack real innovation. This stems from the long-standing disconnect between research, production, and the market during the planned economy era, which has hindered corporate R&D capabilities. In contrast, developed countries adopt a market-driven R&D model, where basic research, development, industrialization, and commercialization are closely linked and led by enterprises. In China, however, the responsibility lies more with research institutions and pharmaceutical companies. Research units conduct basic and some developmental research, while companies engage in limited development and industrialization, with little involvement in fundamental research. This division of labor, which has persisted for over 50 years, has prevented companies from building a solid foundation for independent R&D.
The pharmaceutical industry is known for high risks, high investments, and potentially high returns. Leading multinational pharmaceutical companies typically allocate 10% to 20% of their profits to R&D. For example, Pfizer invests over $5 billion annually in research, while AstraZeneca spends more than $14 million per working day on R&D. In contrast, China's pharmaceutical industry has consistently invested less than 1% of total sales in R&D for many years. Meanwhile, advertising costs can reach 5% to 10% of sales, reflecting an unreasonable distribution system and high sales costs. In foreign markets, over 80% of pharmaceutical sales return to manufacturers, providing strong financial support for future R&D. In China, however, only a small portion of sales—sometimes as low as 10% to 20%—returns to producers. As a result, companies often spend more on market development than on R&D.
Experts argue that true independent innovation in the pharmaceutical sector requires a shift in focus, with enterprises becoming the main drivers. Companies should collaborate closely with research institutions, leveraging their scientific strengths and integrating them into enterprise-led market-oriented management. They should also establish independent R&D teams with strong scientific capabilities. At the same time, it’s crucial to motivate companies to invest in innovative drug development and improve the overall pharmaceutical market environment. The current lack of R&D efforts is closely tied to the existing market conditions. Some well-developed drugs from domestic manufacturers, after years of research and with excellent therapeutic effects, face poor market competitiveness due to higher production costs. As a result, companies focus more on marketing than on innovation. Only when the market becomes fair and competitive will R&D be truly valued.
Some experts predict that if 10% of national retail drug sales were allocated to new drug development, annual revenue could reach 200 billion yuan. This would mean that pharmaceutical companies could invest 20 billion yuan annually in R&D, which is more than ten times the state's investment. In this scenario, the development of “bombshell†new drugs with annual sales exceeding one billion U.S. dollars is just around the corner.
Topic: Plastic Mold frame: the source of efficient production
Plastic Mold holder, as the name suggests, is a mold used to manufacture plastic products. It plays a vital role in modern industrial production, especially in the automotive, electronics, construction and medical fields, plastic mold frame is widely used. With the continuous progress of science and technology, the plastic mold industry is also experiencing unprecedented changes.
The plastic mold holder is characterized by its efficiency, accuracy and reliability. Compared with the traditional mold, the plastic mold frame adopts advanced materials and precision manufacturing process, which can greatly improve production efficiency and reduce production costs. At the same time, the plastic mold frame has a longer service life and lower maintenance costs, which can bring more benefits to enterprises.
In the automotive industry, plastic mold frames are widely used in the manufacture of various plastic parts, such as bumpers, dashboards, seats and so on. These components are not only required to look beautiful, but also to have high strength, corrosion resistance and other characteristics. By using plastic mold frames, car manufacturers can significantly improve production efficiency, reduce costs, and launch new models in a short period of time.
In the electronics industry, plastic mold frames are used to manufacture various precision plastic parts, such as mobile phone cases, computer keyboards, and so on. These parts require not only accurate dimensions, but also good insulation and high temperature resistance. By using plastic mold frames, electronics manufacturers can improve production efficiency and shorten time to market while ensuring product quality.
Plastic Mold holder, as the name suggests, is a mold used to manufacture plastic products. It plays a vital role in modern industrial production, especially in the automotive, electronics, construction and medical fields, plastic mold frame is widely used. With the continuous progress of science and technology, the plastic mold industry is also experiencing unprecedented changes.
The plastic mold holder is characterized by its efficiency, accuracy and reliability. Compared with the traditional mold, the plastic mold frame adopts advanced materials and precision manufacturing process, which can greatly improve production efficiency and reduce production costs. At the same time, the plastic mold frame has a longer service life and lower maintenance costs, which can bring more benefits to enterprises.
In the automotive industry, plastic mold frames are widely used in the manufacture of various plastic parts, such as bumpers, dashboards, seats and so on. These components are not only required to look beautiful, but also to have high strength, corrosion resistance and other characteristics. By using plastic mold frames, car manufacturers can significantly improve production efficiency, reduce costs, and launch new models in a short period of time.
In the electronics industry, plastic mold frames are used to manufacture various precision plastic parts, such as mobile phone cases, computer keyboards, and so on. These parts require not only accurate dimensions, but also good insulation and high temperature resistance. By using plastic mold frames, electronics manufacturers can improve production efficiency and shorten time to market while ensuring product quality.
Die-Casting Mold Base,Terminal Mold Base,Non-Standard Mould Insert processing and manufacturing,Plastic Injection Mould Plastic Parts